Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Baltaleucel-T - Cell Medica

Drug Profile

Baltaleucel-T - Cell Medica

Alternative Names: CMD-003; Cytorex-EBV; EBV-specific cytotoxic T-lymphocytes - CAGT/Cell Medica; EBV-specific T-cells - CAGT/Cell Medica; Epstein Barr virus antigen-activated T-cells - CAGT/Cell Medica; Epstein Barr virus-specific cytotoxic T-lymphocytes - CAGT/Cell Medica; Epstein Barr virus-specific T-cells - CAGT/Cell Medica

Latest Information Update: 27 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baylor College of Medicine
  • Developer Baylor College of Medicine; Cell Medica; Center for Cell and Gene Therapy
  • Class Antineoplastics; Cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Post-transplant lymphoproliferative disorder; Non-Hodgkin's lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma; Nasopharyngeal cancer; Post-transplant lymphoproliferative disorder
  • No development reported Epstein-Barr virus infections

Most Recent Events

  • 21 Feb 2017 Baltaleucel-T receives Fast Track designation for Lymphoma [IV,Infusion] (In adolescents, Second-line therapy or greater, In adults) in USA
  • 21 Feb 2017 Baltaleucel-T receives Fast Track designation for Post-transplant lymphoproliferative disorder [IV,Infusion] (In adolescents, In adults, Second-line therapy or greater) in USA
  • 06 Dec 2016 Efficacy data from the phase II CITADEL and phase I GRALE trial in Lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top